Prime Medicine announces positive Phase 1/2 data for PM359, leadership changes, and strategic pipeline prioritization, focusing on liver diseases. Prime Medicine, Inc. announced initial positive data ...
Prime Medicine reports positive initial Phase 1/2 trial results for PM359, showing safety and efficacy in treating Chronic Granulomatous Disease. Prime Medicine, Inc. has announced positive initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results